Overall survival data from CheckMate-069, a phase II trial of a Opdivo and Yervoy combination regimen in patients with previously untreated advanced melanoma, demonstrated a two-year overall survival rate of 69 percent compared to 53 percent for Yervoy alone (HR=0.58 [95% CI: 0.31-1.08]) in patients with BRAF wild-type advanced melanoma.
A phase III trial of farletuzumab failed to meet its endpoints of significantly increasing progression-free survival or overall survival in ovarian cancer patients.
A phase III trial of PD-1 inhibitor Opdivo showed significant survival benefit at one year—compared to investigator's choice of methotrexate, docetaxel or cetuximab—in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
Two phase III trials in non-small cell lung cancer patients with cachexia found that treatment with anamorelin significantly improved lean body mass and body weight compared to placebo, in addition to improving symptom burden, including appetite. No differences in handgrip strength were observed, one of the co-primary endpoints of the study.
Tocagen Inc. expanded its phase II/III clinical trial Toca 5, and is now enrolling patients in Canada. The trial first began enrolling patients in the U.S. in December 2015.
Updated results from a phase II trial of Reolysin and paclitaxel in ovarian cancer patients showed that an intent-to-treat analysis of tumor response, as assessed by CA-125 antigen levels, demonstrated statistically significantly higher full response rates and stable disease or better rates in the test arm compared to paclitaxel alone.
FDA approved Imbruvica (ibrutinib) as a first-line treatment for patients with chronic lymphocytic leukemia.
Patients with advanced metastatic lung cancer treated with atezolizumab, a targeted immunotherapy drug, lived significantly longer and with fewer side effects than those who received docetaxel chemotherapy, according to a study published in The Lancet.
A phase III trial of Vyxeos Liposome for Injection demonstrated statistically significant improvements in overall survival in patients with high-risk secondary acute myeloid leukemia.
